• share
• favorite_border

People with rare genetic variants associated with Parkinson’s disease and other neurodegenerative disorders are at increased risk of developing amyotrophic lateral sclerosis (ALS), according to new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). The study is the first to find that rare variants linked to other neurodegenerative diseases are associated with ALS, also known as Lou Gehrig’s disease. Researchers also found having these rare variants raises the risk of faster progression of ALS as well as shorter survival.

• share
• favorite_border

Starting patients with multiple sclerosis (MS) on aggressive treatment earlier may help prevent the development of paramagnetic rim lesions (PRL), areas of chronic brain inflammation that are linked to faster decline due to the disease, suggests new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). People with MS who have PRLs tend to have greater brain atrophy and disability. Treatment for MS includes low-, moderate- or high-efficacy disease-modifying therapies (DMTs), such as monoclonal antibodies, immunomodulators and immunosuppressants. While high-efficacy DMTs have more side effects, previous research suggests they may help prevent PRLs from forming (unlike low- or moderate-efficacy DMTs), potentially outweighing the downsides. No currently available DMT has been shown to reduce existing PRLs.

• share
• favorite_border

Artificial intelligence (AI) is poised to revolutionize the care of neurological diseases, from detecting tumors the human eye can’t see and using implantable devices to manage various conditions to crunching data from thousands of people with the same condition to guide the development of new treatments, according to neurologists and biomedical researchers speaking at the Presidential Symposium – Present and Future Applications of AI in Neurological Care and Research at the 149th Annual Meeting of the American Neurological Association (ANA).

• share
• favorite_border

College students who vaped had lower cognitive function scores than those who didn’t, and the more they vaped, the bigger the disparity, according to first-of-its-kind research being presented at the 149th Annual Meeting of the American Neurological Association (ANA). The study also found college students who vaped and smoked had the lowest scores. While using electronic cigarettes (vaping) has been shown to cause lung damage, the research presented at ANA is groundbreaking because there is little to no information on vaping’s relationship to cognitive function, such as learning, memory, problem-solving, critical thinking and decision-making. Cognitive testing is rarely performed in young people.

• share
• favorite_border

Awards will be presented at the ANA2024 Annual Meeting in Orlando.

• share
• favorite_border

The 149th Annual Meeting of the American Neurological Association (ANA) will explore new frontiers in neurology, including the significant progress made in our understanding of the major mutations causing ALS, recent advances in artificial intelligence (AI) that help us better understand the causes, prognosis, and treatment of neurological disease, and new information about encephalitis, a rare and devastating neurologic disease.

• share
• favorite_border

Newly approved anti-amyloid therapies that slow Alzheimer’s disease progression offer new hope for people with the disorder.

• share
• favorite_border

Suffering a traumatic brain injury (TBI) – no matter how severe – is associated with a significantly increased risk of ischemic stroke in a diverse group of U.S. adults, according to new research being presented at the 148th Annual Meeting of the American Neurological Association (ANA). Suffering more than one head injury further increased the risk.

• share
• favorite_border

Nearly 100 drugs for multiple sclerosis (MS), blood cancers, rheumatoid arthritis and other diseases may cause Progressive Multifocal Leukoencephalopathy (PML), a rare but often-fatal condition. A simple genetic test can determine who has a 10-fold higher risk for the condition so they can discuss safer treatment options with their physicians. The largest study to date on drugs that increase the risk for PML and the genetic link to the disease is being presented at the 148th Annual Meeting of the American Neurological Association (ANA).

• share
• favorite_border

Neurological disorders – including autism spectrum disorder (ASD), Alzheimer’s disease and Parkinson’s disease – cause sleep disturbances that make life extra challenging for people with those conditions. Improving sleep not only helps improve their quality of life, evidence is mounting that good sleep is vital for a healthy brain and may reduce the risk of some neurological disorders, according to neurologists speaking at the Presidential Symposium – Exploring Sleep Disturbances in CNS Disorders plenary session at the 148th Annual Meeting of the American Neurological Association (ANA).

• share
• favorite_border

The American Neurological Association (ANA), the professional organization representing the world’s top academic neurologists and neuroscientists, has announced the recipients of its 2023 scientific awards, to be presented during the 148th ANA Annual Meeting, which will be held in person September 9-12, 2023, at the Philadelphia Marriott Downtown in Philadelphia, Pennsylvania.

• share
• favorite_border

The closing plenary session at ANA2022 spotlighted neurologic health inequities and presented new research finding that neighborhood disadvantage strongly predicted likelihood of death from neurologic conditions independent of individual wealth and demographics.

• share
• favorite_border

The Presidential Symposium at the ongoing American Neurological Association 147th Annual Meeting outlined major risks to neurological health from environmental exposures to pesticides, air pollution, synthetic materials, and more — now emerging as a major research area in neuroscience.

• share
• favorite_border

As the American Neurological Association’s 147th Annual Meeting wraps up today, October 25, the ANA is holding a Media Roundtable at 11 a.m. U.S. Central for reporters to access the latest developments in neurology and neuroscience.

• share
• favorite_border

The American Neurological Association (ANA), the professional organization representing the world’s leading academic neurologists and neuroscientists, has appointed Brenda Orffer, CAE, as its new Chief Executive Officer and Nadine Goldberg, PhD, MS, as Chief Program Officer.

• share
• favorite_border

The Presidential Symposium at the American Neurological Association’s 2022 Annual Meeting (ANA2022) in Chicago will shine a spotlight on the role of environmental exposures — air pollution, pesticides, microplastics, and more — in diseases like dementias and developmental disorders.

• share
• favorite_border

Abstracts of breaking research in neurology and neuroscience, to be presented at the 2022 American Neurological Association Annual Meeting Oct. 22-25, are now available in Annals of Neurology and on the ANA2022 website.

• share
• favorite_border

• share
• favorite_border